Tags

Type your tag names separated by a space and hit enter

[Gastric neuroendocrine tumors].

Abstract

Gastrointestinal neuroendocrine tumors are rare neoplasms. Currently, incidence of gastric neuroendocrine tumors (gNETs) is being significantly increased. There are 3 groups of gNETs: types I, II and III. Each type has important features regarding clinical picture, prognosis and treatment strategy. Type I is the most common (70-80%) and associated with chronic atrophic gastritis including autoimmune gastritis and Helicobacter associated atrophic gastritis. Type II (5-6%) is associated with multiple endocrine neoplasia type I and Zollinger-Ellison syndrome (MEN I - ZES). Both types are characterized by hypergastrinemia and small tumor dimension. These neoplasms are multiple and mostly benign. On the contrary, NETs type III (10-15%) is not associated with hypergastrinemia and represented by single large neoplasms. Tumors are malignant as a rule. Therefore, surgical resection and chemotherapy are preferred for these tumors. Endoscopic surgery followed by observation is acceptable for almost all NETS type I and II. At the same time, this approach is advisable only for small and highly differentiated neoplasms type III.

Authors+Show Affiliations

Sechenov First Moscow State Medical University, Moscow, Russia.Sechenov First Moscow State Medical University, Moscow, Russia.Sechenov First Moscow State Medical University, Moscow, Russia.Department of Surgery, SUNY Upstate Medical University, Syracuse, NY, USA.Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia PA, USA.

Pub Type(s)

Journal Article

Language

rus

PubMed ID

31825351

Citation

Alekberzade, A V., et al. "[Gastric Neuroendocrine Tumors]." Khirurgiia, 2019, pp. 111-120.
Alekberzade AV, Krylov NN, Lipnitskiy EM, et al. [Gastric neuroendocrine tumors]. Khirurgiia (Mosk). 2019.
Alekberzade, A. V., Krylov, N. N., Lipnitskiy, E. M., Shakhbazov, R. O., & Azari, F. (2019). [Gastric neuroendocrine tumors]. Khirurgiia, (12), 111-120. https://doi.org/10.17116/hirurgia2019121111
Alekberzade AV, et al. [Gastric Neuroendocrine Tumors]. Khirurgiia (Mosk). 2019;(12)111-120. PubMed PMID: 31825351.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Gastric neuroendocrine tumors]. AU - Alekberzade,A V, AU - Krylov,N N, AU - Lipnitskiy,E M, AU - Shakhbazov,R O, AU - Azari,F, PY - 2019/12/12/entrez PY - 2019/12/12/pubmed PY - 2019/12/25/medline KW - classification KW - diagnosis KW - gastric neuroendocrine tumors KW - pathogenesis KW - prognosis KW - treatment SP - 111 EP - 120 JF - Khirurgiia JO - Khirurgiia (Mosk) IS - 12 N2 - Gastrointestinal neuroendocrine tumors are rare neoplasms. Currently, incidence of gastric neuroendocrine tumors (gNETs) is being significantly increased. There are 3 groups of gNETs: types I, II and III. Each type has important features regarding clinical picture, prognosis and treatment strategy. Type I is the most common (70-80%) and associated with chronic atrophic gastritis including autoimmune gastritis and Helicobacter associated atrophic gastritis. Type II (5-6%) is associated with multiple endocrine neoplasia type I and Zollinger-Ellison syndrome (MEN I - ZES). Both types are characterized by hypergastrinemia and small tumor dimension. These neoplasms are multiple and mostly benign. On the contrary, NETs type III (10-15%) is not associated with hypergastrinemia and represented by single large neoplasms. Tumors are malignant as a rule. Therefore, surgical resection and chemotherapy are preferred for these tumors. Endoscopic surgery followed by observation is acceptable for almost all NETS type I and II. At the same time, this approach is advisable only for small and highly differentiated neoplasms type III. SN - 0023-1207 UR - https://www.unboundmedicine.com/medline/citation/31825351/[Gastric_neuroendocrine_tumors] L2 - https://doi.org/10.17116/hirurgia2019121111 DB - PRIME DP - Unbound Medicine ER -